Renin-angiotensin-aldosterone system inhibition and haemocompatibility-related adverse events in patients with durable left ventricular assist device: the MOMENTUM-3 trial
Listen to this summary
The authors aimed to determine whether inhibition of the renin-angiotensin-aldosterone system (RAASi) is associated with a reduction in hemocompatibility-related adverse events (HRAE) in patients with durable left ventricular assist devices (LVAD). Their analysis of 1,855 patients from the MOMENTUM-3 trial revealed that RAASi therapy significantly lowered the rates of composite HRAEs, particularly non-surgical bleeding, suggesting that pharmacological modulation of neurohormonal pathways could enhance long-term outcomes in LVAD therapy.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.
More from European heart journal
View all →May 10, 2026 · European heart journal
Blinded withdrawal of randomized treatment with low-dose digoxin or placebo in patients with heart failure: the DECISION trial
May 7, 2026 · European heart journal
Environmental risk factors and cardiovascular health
May 6, 2026 · European heart journal
Ultra-processed foods, lifestyle management, and cardiovascular diseases
May 5, 2026 · European heart journal
A nurse-coordinated intervention programme vs standard of care after an acute coronary syndrome: the ALLEPRE trial
May 2, 2026 · European heart journal
Cancer and heart failure: prevalence, incidence, and prognosis in Scotland
Apr 30, 2026 · European heart journal
Direct oral anticoagulants vs warfarin in Asian vs non-Asian patients with atrial fibrillation: a patient-level meta-analysis from COMBINE AF
More in Internal Medicine
View all →May 10, 2026 · JAMA
Efficacy and Safety of Digitalis Glycosides in Heart Failure: A Meta-Analysis
May 10, 2026 · Lancet (London, England)
Enpatoran, a Toll-like receptor 7/8 inhibitor, in moderate-to-severe systemic lupus erythematosus: findings from Cohort B of a multicentre, international, double-blind, placebo-controlled dose-finding phase 2 trial
May 10, 2026 · Lancet (London, England)
Endovascular thrombectomy for patients with large-core ischaemic stroke presenting up to 24 h after onset (ATLAS): a systematic review and individual patient data meta-analysis with central imaging adjudication
May 10, 2026 · JAMA
Digoxin in Patients With Symptomatic Rheumatic Heart Disease: A Randomized Clinical Trial
May 10, 2026 · Lancet (London, England)
Impact of introducing RTS,S/AS01<sub>E</sub> malaria vaccine on mortality in young children in Ghana, Kenya, and Malawi: an observational evaluation of a cluster-randomised implementation programme
May 9, 2026 · The American journal of medicine
From obesity to cardiovascular disease: pathological basis and clinical implications
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR
Stay current without falling behind
33,000+ journals. 3-minute audio summaries. Free for 14 days.
